CYTK Stock: Price, Earnings History and SEC Filings
Cytokinetics, Incorporated (CYTK) last traded at $62.99, down 0.51% on the latest session and down 4.4% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.50 against an analyst estimate of $-1.63, a beat of 8.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
CYTK earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-1.50 | $-1.63 | +7.98% |
| Mar 2026 | May 5, 2026 | $-1.67 | $-1.67 | +0.00% |
| Dec 2025 | Feb 24, 2026 | $-1.50 | $-1.48 | -1.35% |
| Sep 2025 | Nov 5, 2025 | $-1.54 | $-1.59 | +3.14% |
CYTK beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How CYTK reacts to earnings
Across its last 8 earnings releases, CYTK moved 4.1% on average the next session, in either direction. It rose after 2 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | After close | -5.67% |
| 2026-05-05 | After close | -2.92% |
| 2026-02-24 | After close | -10.29% |
| 2025-11-05 | After close | +1.88% |
| 2025-08-07 | After close | -3.23% |
| 2025-05-06 | After close | -2.74% |
| 2025-02-27 | After close | -3.06% |
| 2024-08-08 | After close | +3.31% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
CYTK financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $88M | -$785M | -$535M | -891.6% | $-6.54 |
| 2024 | $18M | -$590M | -$400M | -3191.1% | $-5.26 |
| 2023 | $8M | -$526M | -$416M | -6988.6% | $-5.45 |
| 2022 | $95M | -$389M | -$311M | -411.2% | $-4.33 |
| 2021 | $70M | -$215M | -$191M | -305.7% | $-2.80 |
| 2020 | $56M | -$127M | -$2M | -228.0% | $-1.97 |
| 2019 | $27M | -$122M | -$94M | -452.9% | – |
| 2018 | $32M | -$106M | -$102M | -337.4% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for CYTK
- 8-K · Aug 28, 2026Other events, Financial statements and exhibits
- 8-K · Aug 13, 2026Other events
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 8-K · May 27, 2026Shareholder vote
- 8-K · May 8, 2026Other events, Financial statements and exhibits
- 424B5 · May 7, 2026
- 424B5 · May 5, 2026
- 8-K · May 5, 2026Other events, Financial statements and exhibits
- 10-Q · May 5, 2026
Insider filing activity
CYTK insiders filed 20 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
CYTK news
- Will Alector (ALEC) Report Negative Q3 Earnings? What You Should KnowOct 29, 2026 · finance.yahoo.com
- Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?Oct 28, 2026 · finance.yahoo.com
- Cytokinetics to Announce Third Quarter Results on November 4, 2026Oct 21, 2026 · finance.yahoo.com
- William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates CoverageOct 21, 2026 · finance.yahoo.com
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Oct 19, 2026 · finance.yahoo.com
- BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA SaysOct 19, 2026 · finance.yahoo.com
- Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?Oct 19, 2026 · finance.yahoo.com
- Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic CardiomyopathyOct 19, 2026 · finance.yahoo.com
About Cytokinetics, Incorporated
Cytokinetics, Incorporated (CYTK) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. Its fiscal year ends in December.